Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Endometrial Neoplasms 12Polycystic Ovary Syndrome 4Endometrial Hyperplasia 4Infertility 3Neoplasms 2Anovulation 2Vitamin D Deficiency 1Turcot syndrome 1Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1Adenocarcinoma 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Medroxyprogesterone Acetate × Clear all
NCT00577122 2023-10-16

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

Indiana University

Phase 2 Completed
30 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡